Literature DB >> 22732250

Intermittent administration of recombinant human soluble thrombomodulin successfully controlled chronic disseminated intravascular coagulation in a patient with dissecting aortic aneurysm on an outpatient basis.

Satoshi Iyama1, Tsutomu Sato, Kazuyuki Murase, Yusuke Kamihara, Kaoru Ono, Shohei Kikuchi, Kohichi Takada, Koji Miyanishi, Yasushi Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato.   

Abstract

Chronic disseminated intravascular coagulation (DIC) is a rare but life-threatening complication of dissecting aortic aneurysm. Although anticoagulant therapy may often proves effective for controlling DIC itself, patients would have to be hospitalized for a long period due to continuous infusion therapy. Subcutaneous injection of a highly concentrated preparation of heparin calcium may offer one alternative treatment for DIC; however, daily subcutaneous use of heparin for the treatment of DIC has impaired quality of life (QOL). The other alternative therapy is intravenous administration of recombinant human soluble thrombomodulin (rTM), which includes the active extracellular domain of thrombomodulin. Reportedly, rTM effectively resolves DIC by only 6 consecutive days of administration; however, how frequently rTM should be administered after the resolution of chronic DIC to have good control of it has been unclear. We report herein a case of chronic DIC complicated with dissecting aortic aneurysm, whose resolution of chronic DIC achieved by 6 consecutive days of rTM has been maintained by once a week administration of rTM on an outpatient basis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22732250     DOI: 10.1097/MBC.0b013e32835510d6

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

1.  Aortic aneurysm and chronic disseminated intravascular coagulation: a retrospective study of 235 patients.

Authors:  Yun Zhang; Chen Li; Min Shen; Bao Liu; Xuejun Zeng; Ti Shen
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Incidence, Outcome, and Risk Factors of Cardiovascular Surgery-Associated Disseminated Intravascular Coagulation: A Single-Center Retrospective Study.

Authors:  Norihisa Yasuda; Koji Goto; Yoshihide Kuribayashi; Yoshifumi Ohchi; Takaaki Kitano
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

3.  Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban.

Authors:  Yasuko Kadohira; Shinya Yamada; Erika Matsuura; Tomoe Hayashi; Eriko Morishita; Shinji Nakao; Hidesaku Asakura
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

4.  Successful Treatment with Edoxaban for Disseminated Intravascular Coagulation in a Case of Aortic Dissection Complicated with Immune Thrombocytopenic Purpura.

Authors:  Shun Uemura; Hironori Kobayashi; Yoshinobu Seki; Yuki Okoshi; Hirohito Sone; Nobuhiko Nomoto
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271

5.  Preoperative disseminated intravascular coagulation complicated by thoracic aortic aneurysm treated using recombinant human soluble thrombomodulin: A case report.

Authors:  Yoshinori Tanigawa; Yasutaka Yamada; Kimihide Nakamura; Tomoko Yamashita; Akira Nakagawachi; Yoshiro Sakaguchi
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.